Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy
Carregando...
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
TOMAZ, Samanta Lopes
COSTANZI-STRAUSS, Eugenia
Citação
CANCER IMMUNOLOGY IMMUNOTHERAPY, v.65, n.4, p.371-382, 2016
Resumo
Previously, we combined p19(Arf) (Cdkn2a, tumor suppressor protein) and interferon beta (IFN-beta, immunomodulatory cytokine) gene transfer in order to enhance cell death in a murine model of melanoma. Here, we present evidence of the immune response induced when B16 cells succumbing to death due to treatment with p19(Arf) and IFN-beta are applied in vaccine models. Use of dying cells for prophylactic vaccination was investigated, identifying conditions for tumor-free survival. After combined p19(Arf) and IFN-beta treatment, we observed immune rejection at the vaccine site in immune competent and nude mice with normal NK activity, but not in NOD-SCID and dexamethasone immunosuppressed mice (NK deficient). Combined treatment induced IL-15, ULBP1, FAS/APO1 and KILLER/DR5 expression, providing a mechanism for NK activation. Prophylactic vaccination protected against tumor challenge, where markedly delayed progression and leukocyte infiltration were observed. Analysis of primed lymphocytes revealed secretion of TH1-related cytokines and depletion protocols showed that both CD4(+) and CD8(+) T lymphocytes are necessary for immune protection. However, application of this prophylactic vaccine where cells were treated either with IFN-beta alone or combined with p19(Arf) conferred similar immune protection and cytokine activation, yet only the combination was associated with increased overall survival. In a therapeutic vaccine protocol, only the combination was associated with reduced tumor progression. Our results indicate that by harnessing cell death in an immunogenic context, our p19(Arf) and IFN-beta combination offers a clear advantage when both genes are included in the vaccine and warrants further development as a novel immunotherapy for melanoma.
Palavras-chave
Cell death, p19Arf, Interferon beta, Immunotherapy, Melanoma, Adenovirus
Referências
- Croce M, 2012, IMMUNOTHERAPY-UK, V4, P957, DOI [10.2217/imt.12.92, 10.2217/IMT.12.92]
- Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158
- Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938
- Keil D, 2001, J IMMUNOL, V167, P4543
- Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954
- Sutherland CL, 2006, BLOOD, V108, P1313, DOI 10.1182/blood-2005-11-011320
- Textor S, 2011, CANCER RES, V71, P5998, DOI 10.1158/0008-5472.CAN-10-3211
- Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4
- Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783
- BUDZYNSKI W, 1994, IMMUNOPHARM IMMUNOT, V16, P319, DOI 10.3109/08923979409007097
- Weber JD, 1999, NAT CELL BIOL, V1, P20
- Wang YM, 2012, CELL HOST MICROBE, V11, P631, DOI 10.1016/j.chom.2012.05.003
- de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912
- SHULTZ LD, 1995, J IMMUNOL, V154, P180
- Merkel CA, 2013, CANCER GENE THER, V20, P317, DOI 10.1038/cgt.2013.23
- Oba-Shinjo SM, 2006, NEOPLASIA, V8, P231, DOI 10.1593/neo.05781
- Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4
- Kaufman HL, 2013, NAT REV CLIN ONCOL, V10, P588, DOI 10.1038/nrclinonc.2013.153
- Lu M, 2014, FEBS LETT, V588, P2616, DOI 10.1016/j.febslet.2014.05.008
- Bajgelman MC, 2008, VIROLOGY, V371, P8, DOI 10.1016/j.virol.2007.11.015
- Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
- Wong JL, 2013, CANCER RES, V73, P4653, DOI 10.1158/0008-5472.CAN-12-4366
- Rodrigues L, 2009, EXPERT REV VACCINES, V8, P167, DOI 10.1586/14760584.8.2.167
- Thalanayar Prashanth M, 2014, Chin Clin Oncol, V3, P26, DOI 10.3978/j.issn.2304-3865.2014.03.02
- Yoon SR, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.114